-
Mashup Score: 2
Background: In a randomized, placebo-controlled, clinical trial, bamlanivimab, a SARS-CoV-2–neutralizing monoclonal antibody, given in combination with remdesivir, did not improve outcomes among hospitalized patients with COVID-19 based on an early futility assessment. Objective: To evaluate the a priori hypothesis that bamlanivimab has greater benefit in patients without detectable levels of…
Source: Annals of Internal MedicineCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 2
Background: In a randomized, placebo-controlled, clinical trial, bamlanivimab, a SARS-CoV-2–neutralizing monoclonal antibody, given in combination with remdesivir, did not improve outcomes among hospitalized patients with COVID-19 based on an early futility assessment. Objective: To evaluate the a priori hypothesis that bamlanivimab has greater benefit in patients without detectable levels of…
Source: Annals of Internal MedicineCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
New from @ProfJLundgren: #bamlanivimab may be effective for #COVID19 patients and no detectable levels of endogenous #nAb but may be harmful to patients with an nAB response: https://t.co/5cu2608Pg5 https://t.co/suudAONTGv
-
-
Mashup Score: 1
The monoclonal antibody bamlanivimab may be effective in treating hospitalized patients with SARS-CoV-2 infection if they have no detectable levels of endogenous neutralizing antibodies prior to administration, according to researchers. However, the researchers warned that bamlanivimab (Eli Lilly & Co.) may be harmful to patients who have already mounted an endogenous neutralizing antibody
Source: www.healio.comCategories: General Medicine News, Latest HeadlinesTweet-
#Bamlanivimab may be effective in treating hospitalized patients with SARS-CoV-2 infection if they are seronegative but the treatment may actually be harmful if they are seropositive. @cphiv #COVID19 https://t.co/x430w6390j
-
-
Mashup Score: 221
On September 17, Mayra Arana made the phone call she says saved her life.
Source: CNNCategories: Infectious Disease, Latest HeadlinesTweet-
RT @RazonableMD This news piece comes at a time when the Monoclonal Antibody Treatment MATRx Program surpasses 14,000 patients with covid-19 infused with these lifesaving antibodies - CNN #casirivimab #bamlanivimab #sotrovimab https://t.co/qYBdCQwy2O
-
-
Mashup Score: 27
On September 17, Mayra Arana made the phone call she says saved her life.
Source: CNNCategories: Healthcare Professionals, Latest HeadlinesTweet-
Doctors are often unaware of the only treatment for early Covid-19 monoclonal antibodies - which reduce risk of #covid hospitalizations/death by 70% to 85% but @mayoclinic used EHR + education to proactively screen and reach out to patients - via @CNN https://t.co/24v6UFgipQ
-
Monoclonal antibodies as treatment for early Covid-19 - CNN @MayoClinicINFD #casirivimab #bamlanivimab #sotrovimab https://t.co/u47NnzVdpf
-
-
Mashup Score: 3JCI - Intravenous bamlanivimab use associates with reduced hospitalization in high-risk patients with mild to moderate COVID-19 - 3 year(s) ago
Clinical MedicineVirology Free access | 10.1172/JCI151697 Colin F. Pawlowski,2 John C. O’Horo,1 Lori L. Arndt,3 Richard F. Arndt,3 Sarah J. Bell,1 Dennis M. Bierle,1 Molly Destro Borgen,1 Sara N. Hanson,4 Alexander Heyliger,1 Jennifer J. Larsen,1 Patrick J. Lenehan,2 Robert Orenstein,5…
Source: www.jci.orgCategories: Infectious Disease, Latest HeadlinesTweet-
#JCI - #bamlanivimab associates with reduced #hospitalization, ICU admission and mortality in >4600 high-risk patients with mild to moderate #COVID19 @jclinicalinvest @MayoClinicINFD @MayoClinic https://t.co/3uVdljiKTI
-
-
Mashup Score: 1JCI - Intravenous bamlanivimab use associates with reduced hospitalization in high-risk patients with mild to moderate COVID-19 - 3 year(s) ago
Clinical MedicineIn-Press PreviewVirology Free access | 10.1172/JCI151697 Colin F. Pawlowski,2 John C. O’Horo,3 Lori L. Arndt,4 Richard F. Arndt,5 Sarah Bell,6 Dennis M. Bierle,1 Molly Destro Borgen,7 Sara Hanson,8 Alexander Heyliger,9 Jennifer L. Larsen,6 Patrick J. Lenehan,10 Robert…
Source: www.jci.orgCategories: Infectious Disease, Latest HeadlinesTweet-
Findings are similar to the results of #bamlanivimab prior to emergence of resistant variants of concern. This larger @jclinicalinvest cohort study allowed for analysis that also showed lower ICU admission and mortality with mAbs. https://t.co/3uVdljiKTI @Ravi_Ganesh_MD https://t.co/2T5nOOKXi9
-
-
Mashup Score: 4
The monoclonal antibody LY-CoV555 (bamlanivimab) increases viral clearance after a single infusion in high-risk outpatients.1,2 In previous studies, variant escape mutation after bamlanivimab monotherapy occurred in less than 12% of patients within 29 days.1,2 However, immunocompromised patients were not included in these clinical trials. Here, we report virological and clinical follow-up of the…
Source: The Lancet MicrobeCategories: Infectious Disease, Latest HeadlinesTweet-
RT @LancetMicrobe: New correspondence> #Bamlanivimab as monotherapy in two immunocompromised patients with #COVID19 https://t.co/Wi68kNUCVi
-
-
Mashup Score: 0Lilly Asks FDA to Revoke its EUA for Bamlanivimab Alone - 3 year(s) ago
The company wants to transition to combination therapy of bamlanivimab and etesevimab together for COVID-19 treatment.
Source: Contagion LiveCategories: Infectious Disease, Latest HeadlinesTweet-
The company wants to transition to combination therapy of #bamlanivimab and #etesevimab together for #COVID19 treatment. https://t.co/mWAN96EsyA
-
-
Mashup Score: 13New Data Show Authorized Dose of Bamlanivimab-Etesevimab Cuts COVID-19 Hospitalizations, Death - 3 year(s) ago
New BLAZE-1 clinical trial data show bamlanivimab plus etesevimab significantly reduce COVID-19 related hospitalizations and deaths in high-risk patients.
Source: Infectious Disease AdvisorCategories: Infectious Disease, Latest HeadlinesTweet-
Bamlanivimab and etesevimab together and #bamlanivimab alone are authorized under Emergency Use Authorization. https://t.co/42RdUpsmDE
-
#ICYMI: #bamlanivimab may be effective for #COVID19 patients and no detectable levels of endogenous #nAb but may be harmful to patients with an nAB response: https://t.co/5cu2608Pg5